11 results about "MLH1" patented technology

The present technology relates to methods for excluding Lynch syndrome as a possible diagnosis in patients suffering from colorectal cancers or endometrial cancers. These methods are based on detecting the methylation status of the MLH1 promoter ‘C’ region in colorectal and endometrial cancer patients using an improved and highly sensitive methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) assay.

The invention belongs to the technical field of antibody preparation, and particularly relates to an anti-MLH1 protein monoclonal antibody and application thereof in immunodetection. Amino acid sequences of CDR1-3 on a light chain variable region of the antibody are respectively shown as SEQ ID NO.3-5, and amino acid sequences of CDR1-3 on a heavy chain variable region of the antibody are respectively shown as SEQ ID NO.8-10. The antibody provided by the invention has strong specificity, high recognition sensitivity and good binding affinity for human MLH1 protein in cells and tissues, can accurately recognize and locate target protein in cells and tissues, greatly reduces the occurrence rate of false positive and false negative results, and can be applied to a plurality of immunodetection systems, such as human MLH1 protein, human MLH1 protein, human MLH1 protein, human MLH1 protein, human MLH1 protein and human MLH1 protein. Particularly, the method has good applicability in immunoblotting and immunohistochemical systems. Moreover, the antibody provided by the invention has cross reactivity to human and mouse homologous MLH1 proteins, and also has certain applicability and good application prospects in detection of mouse MLH1 proteins.

The invention relates to a capture probe group, a kit and a method for detecting hepatobiliary tumor genetic susceptibility gene polymorphism, and belongs to the technical field of biology. The nucleotide sequences of the capture probe group provided by the invention are as shown in SEQ ID NO. 1 to SEQ ID NO. 445; the hepatobiliary tumor genetic susceptibility gene comprises at least one of APC, ATM, ATR, BAP1, BRCA1, BRCA2, FANCA, MLH1, MSH2, MSH6, PALB2, PMS2 and RAD51D. The invention also provides a kit containing the capture probe group and a detection method. The method has the advantages that the coverage area is wide, the embryonic line variation of all exon areas can be detected, the designed capture probe covers the full coding area sequence of the related gene, the coverage degree of the target area reaches 100%, and the average sequencing depth reaches 100 *.

Methods of treating a cancer comprising a mutation in tumor protein p53 (TP53) or DNA mismatch repair protein Mlhl (MLH1) comprising: determining the cancer comprises the mutation and administering an agent that decreases abundance or function of a protein synthetically lethal with TP53 or MLH1 are provided. Agents that decrease abundance or function of a protein synthetical lethal with TP53 or MLH1 for use in treating a cancer comprising a mutation in TP53 or MLH1 are also provided.

The present disclosure discloses a library construction method for detecting endometrial cancer-related gene mutations based on high-throughput sequencing, and belongs to the field of biotechnology. The method can detect the mutation types of endometrial cancer-related genes MSH2, PMS2, MLH1, MSH6 EPCAM, TP53, POLE, and PTEN in surgically removed fresh pathological tissues, formaldehyde-fixed and paraffin-embedded pathological tissues, paraffin sections, and specimens of whole blood, plasma, serum, and pleural effusion, etc. It may be used for multiple target sequences in a single tube to quickly complete the library construction. The entire library construction process only takes 3 hours, and the manual operation only needs 30 minutes. Combined with high-throughput sequencing, the platform may effectively solve the current difficulty in the detection of somatic multi-gene all-exon mutations in clinical endometrial cancer samples based on small numbers of clinical samples, and the cost is low.

The invention relates to an ovarian cancer targeted medication related gene NGS detection kit and application thereof, and the kit comprises a probe group used for detecting ovarian cancer targeted medication related gene variation conditions and corresponding reagents based on a next generation sequencing technology. By means of a hybrid capture method, variation site conditions of 12 genes (BRAF, NTRK1, NTRK2, NTRK3, RET, MLH1, MSH2, MSH6, PMS2, BRCA1, BRCA2 and KRAS) related to important targeted medication of ovarian cancer can be detected at a time. The probe used in the invention has the advantages of wide coverage, high sequencing depth and strong specificity to ovarian cancer patients, and compared with polygene solid tumor large panel detection, the resource waste caused by irrelevant gene detection is reduced, and the reduction of the detection cost and the improvement of the detection efficiency are realized.

The present invention relates to a novel polypeptide that binds to MLH1 to inhibit its interaction with PMS2 and the formation of the MutLα complex, thereby enhancing prime editing efficiency, and uses thereof for prime editing. The polypeptide according to the present invention binds to MLH1 protein to inhibit the formation of a complex with PMS2, resulting in a significant improvement in prime editing efficiency while exhibiting remarkably low off-target editing and cellular toxicity. Furthermore, with a significantly smaller size compared to conventional dominant-negative MLH1 (MLH1dn), the polypeptide of the present invention can be easily integrated into various existing prime editing systems and one vector and is universally applicable. Therefore, the novel MLH1-binding polypeptide of the present invention and the nucleic acid encoding same can be advantageously used in the field of gene editing.

The invention relates to the technical field of synthetic biology and metabolic engineering. The invention provides a saccharomyces cerevisiae recombinant strain capable of improving vanillin tolerance and a construction method thereof, which are characterized in that related genes MSH1, MSH2, MSH3, MSH4, MSH5, MSH6, MLH1, MLH2, MLH3 or PMS1 of a strain DNA mismatch repair system are innovatively knocked out, so that the adaptive evolution ability of the strain is enhanced, and the limitation of traditional metabolic engineering modification is broken through; a stepped vanillin concentration domestication strategy is utilized, and a mutant strain with remarkably improved tolerance is obtained through screening. The limitation of vanillin toxicity on thallus growth and product synthesis is effectively relieved, and a certain foundation is laid for constructing an efficient vanillin biosynthesis system.

The invention provides a composition and a kit for detecting combined methylation of CpG sites in an MLH1 gene target region in human tumor tissues and application of the composition and the kit. The CpG locus combination in the MLH1 gene target area in the human tumor tissue provided by the invention comprises 10 CpG loci which have the most significant difference with methylation states in sporadic and Lingchi syndrome related tumors in the MLH1 gene. The detection composition is designed on the basis of 10 CpG loci, competitive Blocker oligonucleotides are introduced into the detection composition and can be specifically combined with a conversion sequence corresponding to non-methylated DNA, non-specific amplification of the detection composition is effectively inhibited in the early stage of PCR amplification, the common problem of'tail raising 'or background rising in conventional qPCR is thoroughly solved, and the detection composition has the advantages of high specificity, high sensitivity and the like. It is ensured that amplification signals are completely derived from target methylation alleles, the detection specificity is close to 100%, and extremely high confidence is provided for clinical diagnosis.

The present invention relates to compounds of Formula (I) that target the MLH1 and / or PMS2 proteins that are components of the DNA Mismatch Repair (MMR) process:wherein R1, R2, R3, R4, R6 and R10 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which MLH1 and / or PMS2 activity is implicated.

This invention relates to the field of early cancer diagnostic reagents, specifically to a non-invasive intelligent diagnostic kit for early colorectal cancer based on peripheral blood and its application. The kit targets key gene mutation sites (MLH1 c.113del A, MSH2 c.788del A, MUTYH c.1005 G>C, PMS2 c.288 C>T, and c.780 C>G) screened in the Chinese population and includes a specific primer set, circulating tumor DNA (ctDNA) extraction, and sequencing library preparation reagents. The accompanying detection system analyzes mutation data using a logistic regression model trained on the aforementioned sites to achieve early screening. Clinical trials have shown that this method has good performance in early colorectal cancer screening in the Chinese population.